Frederic J. Reu

Frederic J. Reu

Auto-generated profile, based on publicly available information

Frederic J. Reu

Deciphera Pharmaceuticals, LLC., a member of ONO Pharma, Waltham, Massachusetts 02451, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Lancet
Verified
Journal Article
Closed access
BDBrian Durie
Brian Durie
AHAntje Hoering
Antje Hoering
MAMuneer H Abidi
Muneer H Abidi
SRS Vincent Rajkumar
S Vincent Rajkumar
JEJoshua Epstein
Joshua Epstein
ADAngela Dispenzieri
Angela Dispenzieri

4 October 2012 in Blood
Verified
Journal Article
Open access
PDF file
DSDavid S. Siegel
David S. Siegel
TMThomas Martin
Thomas Martin
MWMichael Wang
Michael Wang
RVRavi Vij
Ravi Vij
AJAndrzej J. Jakubowiak
Andrzej J. Jakubowiak
SJSundar Jagannath
Sundar Jagannath
Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg/m2 intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg/m2 for ≤ 12 cycles. The primary endpoint was overall response rate (≥ partial response). Secondary endpoints included clinical benefit response rate (≥ minimal response), duration of response, progression-free survival, overall survival, and safety. A total of 266 patients were evaluable for safety, 257 for efficacy; 95% were refractory to their last therapy; 80% were refractory or intolerant to both bortezomib and lenalidomide. Patients had median of 5 prior lines of therapy, including bortezomib, lenalidomide, and thalidomide. Overall response rate was 23.7% with median duration of response of 7.8 months. Median overall survival was 15.6 months. Adverse events (AEs) were manageable without cumulative toxicities. Common AEs were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%). Thirty-three patients (12.4%) experienced peripheral neuropathy, primarily grades 1 or 2. Thirty-three patients (12.4%) withdrew because of an AE. Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit. This trial was registered at www.clinicaltrials.gov as #NCT00511238.

30 April 2004 in Cell Death & Differentiation
Verified
Journal Article
Closed access
MCM Chawla-Sarkar
M Chawla-Sarkar
SBS I Bae
S I Bae
FRF J Reu
F J Reu
BJB S Jacobs
B S Jacobs
DLD J Lindner
D J Lindner
EBE C Borden
E C Borden

11 May 2020 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
BDBrian Durie
Brian Durie
AHAntje Hoering
Antje Hoering
RSRachael Sexton
Rachael Sexton
MAMuneer H. Abidi
Muneer H. Abidi
JEJoshua Epstein
Joshua Epstein
BBBart Barlogie
Bart Barlogie
SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible and analyzable patients were randomized to Rd and 235 to VRd. The 6-month induction was six 28-day cycles of Rd and eight 21-day cycles of VRd followed by Rd maintenance for all patients. Median follow up is 84 months. Median PFS is 41 months for VRd and 29 months for Rd: stratified hazard ratio (96% Wald Confidence Interval) was 0.742 (0.594, 0.928) and one-sided stratified log-rankP-value 0.003. Median OS for VRd is still not reached with median OS for Rd being 69 months: stratified hazard ratio (96% Wald Confidence Interval) was 0.709 (0.543, 0.926) and stratified two-sidedP-value was 0.0114. Both PFS and OS were improved with VRd versus Rd adjusting for age (P-values: 0.013 [PFS]; 0.033 [OS])). Median duration of Rd maintenance was 17.1 months. The addition of bortezomib to lenalidomide dexamethasone for induction therapy results in a statistically significant and clinically meaningful improvement in PFS as well as better OS. VRd continues to represent an appropriate standard of care irrespective of age.

14 June 2012 in Blood
Verified
Journal Article
Open access
PDF file
RVRavi Vij
Ravi Vij
MWMichael Wang
Michael Wang
JKJonathan L. Kaufman
Jonathan L. Kaufman
SLSagar Lonial
Sagar Lonial
AJAndrzej J. Jakubowiak
Andrzej J. Jakubowiak
DSDavid S. Siegel
David S. Siegel
Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R MM). In the present phase 2, multicenter, open-label study, 129 bortezomib-naive patients with R/R MM (median of 2 prior therapies) were separated into Cohort 1, scheduled to receive intravenous carfilzomib 20 mg/m2 for all treatment cycles, and Cohort 2, scheduled to receive 20 mg/m2 for cycle 1 and then 27 mg/m2 for all subsequent cycles. The primary end point was an overall response rate (≥ partial response) of 42.4% in Cohort 1 and 52.2% in Cohort 2. The clinical benefit response (overall response rate + minimal response) was 59.3% and 64.2% in Cohorts 1 and 2, respectively. Median duration of response was 13.1 months and not reached, and median time to progression was 8.3 months and not reached, respectively. The most common treatment-emergent adverse events were fatigue (62.0%) and nausea (48.8%). Single-agent carfilzomib elicited a low incidence of peripheral neuropathy—17.1% overall (1 grade 3; no grade 4)—in these pretreated bortezomib-naive patients. The results of the present study support the use of carfilzomib in R/R MM patients. This trial is registered at www.clinicaltrials.gov as NCT00530816.

10 February 2017 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
SKShaji K. Kumar
Shaji K. Kumar
NCNatalie S. Callander
Natalie S. Callander
MAMelissa Alsina
Melissa Alsina
DADjordje Atanackovic
Djordje Atanackovic
JBJ. Sybil Biermann
J. Sybil Biermann
RKRashmi Kumar
Rashmi Kumar
Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.